

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION September 26, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3963.1000-000		APPLICATION NO. 10/550982	
	FIRST NAMED INVENTOR Peter David Davis		FILING DATE 26 March 2004 (PCT)	
	EXAMINER M. BARKER		CONFIRMATION NO.	GROUP 1626

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/MB/	A1	5,430,062	07-04-1995	Cushman <i>et al.</i>
	A2			
	A3			
	A4			
	A5			
	A6			
	A7			
	A8			
	A9			
	A10			
	A11			
	A12			
	A13			
	A14			
	A15			
	A16			
	A17			
	A18			
	A19			
	A20			
	A21			
	A22			
	A23			
	A24			
	A25			

EXAMINER	DATE CONSIDERED
-----------------	------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION September 26, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3963.1000-000	APPLICATION NO. 10/550982	
	FIRST NAMED INVENTOR Peter David Davis		FILING DATE 26 March 2004 (PCT)
	EXAMINER M.BARKER	CONFIRMATION NO.	GROUP 1626

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/MB/	B1	WO 01/12579 A2	02-22-2001	Angiogene Pharm Ltd.; Davis, Peter David (GB)		
/MB/	B2	WO 00/48590	08-24-2000	Angiogene Pharm Ltd.; Davis, Peter David (GB)		
/MB/	B3	WO 02/50007 A2	06-27-2002	Cancer Res. Ventures Ltd.		
/MB/	B4	WO 2004/085421 A2	10-07-2004	Angiogene Pharm Ltd; Gray Lab. Cancer Research Trust		
	B5					
	B6					
	B7					
	B8					
	B9					
	B10					
	B11					
	B12					
	B13					
	B14					
	B15					
	B16					
	B17					
	B18					
	B19					
	B20					
	B21					
	B22					
	B23					
	B24					

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION September 26, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3963.1000-000	APPLICATION NO. 107550982	
	FIRST NAMED INVENTOR Peter David Davis		FILING DATE 26 March 2004 (PCT)
	EXAMINER M. BARKER	CONFIRMATION NO.	GROUP 626

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/MB/	C1	Pettit, <i>et al.</i> , "Antineoplastic Agents 322. Synthesis of Combretastin A-4 Prodrugs", <i>Anti-Cancer Drug Design, Basingstoke, GB, 10(4):299-309</i> (4 June 1995).
/MB/	C2	Cushman <i>et al.</i> , "Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents that Inhibit Tubulin Polymerization", <i>J. of Med. Chem., American Chemistry Society, 34(8):2579-2588</i> (August 1, 1991).
/MB/	C3	Ohsumi <i>et al.</i> , "Novel Combretastatin Analogues Effective Against Murine Solid Tumors: Design and Structure-Activity Relationships", <i>J. of Med. Chem., American Chemistry Society, 41(16):3022-3032</i> (1998).
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	

EXAMINER /Michael Barker/	DATE CONSIDERED 11/01/2007
------------------------------	-------------------------------

PTO-1449 REPRODUCED

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

May 10, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3963.1000-000

APPLICATION NO.
10/550,982

FIRST NAMED INVENTOR
Peter David Davis

371(c) FILING DATE
October 27, 2005

EXAMINER
Barker, Michael P.

CONFIRMATION NO.
1643

GROUP
1626




U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/MB/	A2	4,996,237	02-26-1991	Pettit <i>et al.</i>
↓	A3	5,569,786	10-29-1996	Pettit <i>et al.</i>
↓	A4	5,633,158	05-27-1997	Anlezark <i>et al.</i>
↓	A5	5,731,353	03-24-1998	Ohsumi <i>et al.</i>
/MB/	A6	5,977,065	11-02-1999	Anlezark <i>et al.</i>
	A7			
	A8			
	A9			
	A10			
	A11			
	A12			
	A13			
	A14			
	A15			
	A16			
	A17			
	A18			
	A19			
	A20			

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3963.1000-000		APPLICATION NO. 10/550,982	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION  May 10, 2007 (attach several sheets if necessary)		FIRST NAMED INVENTOR Peter David Davis		371(c) FILING DATE October 27, 2005	
		EXAMINER Barker, Michael P.		CONFIRMATION NO. 1643	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
/MB/	B5	WO 00/47725 A1	08-17-2000	Microbiological Research Authority		
/MB/	B6	WO 00/64864 A1	11-02-2000	Cancer Research Campaign Technology Limited		
	B5					
	B6					
	B7					
	B8					
	B9					
	B10					
	B11					
	B12					
	B13					
	B14					
	B15					
	B16					
	B17					
	B18					
	B19					
	B20					


EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

May 10, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3963.1000-000APPLICATION NO.
10/550,982FIRST NAMED INVENTOR
Peter David Davis371(c) FILING DATE
October 27, 2005EXAMINER
Barker, Michael P.CONFIRMATION NO.
1643GROUP
1626
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/MB/	C4	Kennedy, Katherine A., <i>et al.</i> , "Preferential Activation of Mitomycin C to Cytotoxic Metabolites by Hypoxic Tumor Cells", <i>Cancer Research</i> , 40:2356-2360 (1980).
	C5	Denny, William A., "The Role of Hypoxia-Activated Prodrugs in Cancer Therapy", <i>The Lancet Oncology</i> , 1:25-29 (2000).
	C6	Rothschild, Bruce M., <i>et al.</i> , "Pathogenesis of Rheumatoid Arthritis: A Vascular Hypothesis", <i>Seminars in Arthritis and Rheumatism</i> , 12(1):11-31 (1982).
	C7	Dvorak, Harold F., "Vascular Permeability Factor/Vascular Endothelial Growth Factor: An Important Mediator of Angiogenesis in Malignancy and Inflammation", <i>Int. Arch. Allergy Immunol.</i> , 107:233-235 (1995).
	C8	Das, Arup, <i>et al.</i> , "Retinal and Choroidal Angiogenesis: Pathophysiology and Strategies for Inhibition", <i>Progress in Retinal and Eye Research</i> , 22:721-748 (2003).
	C9	Naylor, M. A., <i>et al.</i> , "Recent Advances in Bioreductive Drug Targeting", <i>Mini Reviews in Medicinal Chemistry</i> , 1:17-29 (2001).
	C10	Tercel, Moana, <i>et al.</i> , "Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine", <i>J. Med. Chem.</i> , 44:3511-3522 (2001).
	C11	Damen, Eric W.P., <i>et al.</i> , "Synthesis of Novel Paclitaxel Prodrugs Designed for Bioreductive Activation in Hypoxic Tumour Tissue", <i>Bioorganic & Medicinal Chemistry</i> , 10:71-77 (2002).
	C12	Papot, S., <i>et al.</i> , "Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies", <i>Curr. Med. Chem. - Anti-Cancer Agents</i> , 2:155-185 (2002).
↓	C13	Skelly, Jane V., <i>et al.</i> , "Aerobic Nitroreduction by Flavoproteins: Enzyme Structure, Mechanisms, and Role in Cancer Chemotherapy", <i>Mini Reviews in Medicinal Chemistry</i> , 1:293-306 (2001).
/MB/	C14	Woods, J.A., <i>et al.</i> , "The Interaction with Tubulin of a Series of Stilbenes Based on Combretastatin A-4", <i>British Journal of Cancer</i> , 71:705-711 (1995).
	C15	
	C16	

EXAMINER

/Michael Barker/

DATE CONSIDERED

11/01/2007